Dan Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dan Liu has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
- Qinglei Gao
Department of Obstetrics and Gynecology, National Clinical Research Center for Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Key Laboratory of Cancer Invasion and Metastasis (Ministry of Education), Hubei Key Laboratory of Tumor Invasion and Metastasis, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
12 shared publications Ding Ma
Department of Obstetrics and Gynecology, National Clinical Research Center for Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
5 shared publicationsWen Pan
National Clinical Research Center for Obstetrics and Gynecology, Department of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
5 shared publications- Yong Fang
Department of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
5 shared publications Cheng Xu
National Clinical Research Center for Obstetrics and Gynecology, Department of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
4 shared publications- Guang-Nian Zhao
Department of Obstetrics and Gynecology, National Clinical Research Center for Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
4 shared publications
Latest Publications
- Open Access
- 26 June 2026
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 19 (1)
The DAPK3-DCAF1 pathway regulates ZBP1 protein stability to orchestrate PANoptosis for ovarian cancer therapy
Ovarian cancer is characterized by an immunosuppressive "cold" tumor microenvironment, which poses a major challenge to effective therapy. Inducing immunogenic cell death through PANoptosis represents a promising strategy for remodeling the tumor microenvironment. Z-DNA binding protein 1 (ZBP1), an interferon (IFN)-stimulated gene, is a key sensor of Z-conformation nucleic acids (Z-NA) driving PANoptosis. While ZBP1 upregulation is traditionally attributed to transcriptional induction, its early non-transcriptional regulatory mechanisms remain elusive. ZBP1 expression and its prognostic value were analyzed using public databases and clinical cohorts. APEX2 proximity labeling, PLA and Co-IP identified the E3 ubiquitin ligase regulating ZBP1. The IFN-mediated ZBP1 post-translational modification pathway was delineated utilizing PLA, Co-IP, in vitro phosphorylation, mutagenesis assays, an intestine-specific conditional knockout model. DCAF1-/- ovarian cancer cells and immunocompetent ID8 peritoneal models were generated to evaluate tumor growth and cell death. The therapeutic efficacy of combining the DCAF1 inhibitor (B32B3) with the Z-NA inducer (CBL0137) was assessed in an immunocompetent ID8 murine peritoneal tumor model and two chemoresistant patient-derived xenograft (PDX) models. ZBP1 is significantly downregulated in ovarian cancer, whereas its elevated expression predicts a favorable prognosis and correlates with high IFN responsiveness. Type I IFN triggers a rapid accumulation of ZBP1 protein prior to its transcriptional upregulation. Mechanistically, we identified the E3 ligase substrate receptor DCAF1 as a negative regulator that targets ZBP1 for proteasomal degradation. Interferon signaling activates the kinase DAPK3, which phosphorylates DCAF1 at S1328. This phosphorylation event compromises the assembly of the CRL4DCAF1 complex, thereby abrogating DCAF1-mediated degradation of ZBP1. In ovarian cancer models, genetic ablation of DCAF1 restored ZBP1 levels and significantly restrained tumor progression. Therapeutically, combining B32B3 with CBL0137 elevated intracellular Z-NA and stabilized ZBP1, driving PANoptosis and suppressing ovarian tumor growth across. Our study identifies the IFN-DAPK3-DCAF1 pathway as a critical post-translational mechanism that ensures rapid ZBP1 stabilization. This highlights a fundamental strategy to bypass transcriptional latency for the rapid activation of immune responses, offering a strong clinical rationale to harness this pathway to induce ZBP1-dependent PANoptosis for the treatment of refractory tumors.
- 26 June 2026
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 19 (1)
Open AccessThe DAPK3-DCAF1 pathway regulates ZBP1 protein stability to orchestrate PANoptosis for ovarian cancer therapy
Ovarian cancer is characterized by an immunosuppressive "cold" tumor microenvironment, which poses a major challenge to effective therapy. Inducing immunogenic cell death through PANoptosis represents a promising strategy for remodeling the tumor microenvironment. Z-DNA binding protein 1 (ZBP1), an interferon (IFN)-stimulated gene, is a key sensor of Z-conformation nucleic acids (Z-NA) driving PANoptosis. While ZBP1 upregulation is traditionally attributed to transcriptional induction, its early non-transcriptional regulatory mechanisms remain elusive. ZBP1 expression and its prognostic value were analyzed using public databases and clinical cohorts. APEX2 proximity labeling, PLA and Co-IP identified the E3 ubiquitin ligase regulating ZBP1. The IFN-mediated ZBP1 post-translational modification pathway was delineated utilizing PLA, Co-IP, in vitro phosphorylation, mutagenesis assays, an intestine-specific conditional knockout model. DCAF1-/- ovarian cancer cells and immunocompetent ID8 peritoneal models were generated to evaluate tumor growth and cell death. The therapeutic efficacy of combining the DCAF1 inhibitor (B32B3) with the Z-NA inducer (CBL0137) was assessed in an immunocompetent ID8 murine peritoneal tumor model and two chemoresistant patient-derived xenograft (PDX) models. ZBP1 is significantly downregulated in ovarian cancer, whereas its elevated expression predicts a favorable prognosis and correlates with high IFN responsiveness. Type I IFN triggers a rapid accumulation of ZBP1 protein prior to its transcriptional upregulation. Mechanistically, we identified the E3 ligase substrate receptor DCAF1 as a negative regulator that targets ZBP1 for proteasomal degradation. Interferon signaling activates the kinase DAPK3, which phosphorylates DCAF1 at S1328. This phosphorylation event compromises the assembly of the CRL4DCAF1 complex, thereby abrogating DCAF1-mediated degradation of ZBP1. In ovarian cancer models, genetic ablation of DCAF1 restored ZBP1 levels and significantly restrained tumor progression. Therapeutically, combining B32B3 with CBL0137 elevated intracellular Z-NA and stabilized ZBP1, driving PANoptosis and suppressing ovarian tumor growth across. Our study identifies the IFN-DAPK3-DCAF1 pathway as a critical post-translational mechanism that ensures rapid ZBP1 stabilization. This highlights a fundamental strategy to bypass transcriptional latency for the rapid activation of immune responses, offering a strong clinical rationale to harness this pathway to induce ZBP1-dependent PANoptosis for the treatment of refractory tumors.
- Top Cited Papers
- 27 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (851) , eady2719
Genomic instability drives POSTN + myofibroblasts via STING-WNT axis to promote immunosuppression and PARPi resistance in ovarian cancer
Cancer-associated fibroblasts (CAFs) are central architects of immunosuppression and therapy resistance across malignancies, yet how tumor-intrinsic genomic instability instructs stromal reprogramming remains unresolved. Integrated single-cell transcriptomics and epigenomics of samples from patients with high-grade serous ovarian carcinoma revealed POSTN + myofibroblast-like cancer-associated fibroblasts (myCAFs) and effector regulatory T cells (eT reg cells) as critical mediators of immunosuppression in tumors with high genomic instability. Mechanistically, unstable genomes activated tumor-intrinsic STING signaling, triggering WNT3a/7a secretion. WNT/β-catenin signaling in fibroblasts established a POSTN-dependent positive feedback loop that epigenetically locked cells into a POSTN + myCAF lineage. These myCAFs reciprocally expanded eT reg cells and exhausted CD8 + T cells, thereby converting genomic instability–driven immune activation into suppression and limiting poly(ADP-ribose) polymerase inhibitor (PARPi) efficacy. Therapeutic POSTN blockade reinvigorated T cell cytotoxicity, depleted eT reg cells, and potentiated PARP inhibition in ovarian and breast cancer models, overcoming resistance. Our work resolves the dual roles of genomic instability and identifies POSTN as a stromal-specific checkpoint to mediate immunosuppression in genomically unstable tumors.
- 27 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (851) , eady2719
Top Cited PapersGenomic instability drives POSTN + myofibroblasts via STING-WNT axis to promote immunosuppression and PARPi resistance in ovarian cancer
Cancer-associated fibroblasts (CAFs) are central architects of immunosuppression and therapy resistance across malignancies, yet how tumor-intrinsic genomic instability instructs stromal reprogramming remains unresolved. Integrated single-cell transcriptomics and epigenomics of samples from patients with high-grade serous ovarian carcinoma revealed POSTN + myofibroblast-like cancer-associated fibroblasts (myCAFs) and effector regulatory T cells (eT reg cells) as critical mediators of immunosuppression in tumors with high genomic instability. Mechanistically, unstable genomes activated tumor-intrinsic STING signaling, triggering WNT3a/7a secretion. WNT/β-catenin signaling in fibroblasts established a POSTN-dependent positive feedback loop that epigenetically locked cells into a POSTN + myCAF lineage. These myCAFs reciprocally expanded eT reg cells and exhausted CD8 + T cells, thereby converting genomic instability–driven immune activation into suppression and limiting poly(ADP-ribose) polymerase inhibitor (PARPi) efficacy. Therapeutic POSTN blockade reinvigorated T cell cytotoxicity, depleted eT reg cells, and potentiated PARP inhibition in ovarian and breast cancer models, overcoming resistance. Our work resolves the dual roles of genomic instability and identifies POSTN as a stromal-specific checkpoint to mediate immunosuppression in genomically unstable tumors.
- Open Access
- 31 March 2026
- Published by Elsevier in Cell Reports
- Vol. 45 (4) , 117198
PTEN loss drives B7H3 upregulation via the mTORC2/FOXO/c-Myc axis to promote tumor immune escape in ovarian cancer
- 31 March 2026
- Published by Elsevier in Cell Reports
- Vol. 45 (4) , 117198
Open AccessPTEN loss drives B7H3 upregulation via the mTORC2/FOXO/c-Myc axis to promote tumor immune escape in ovarian cancer
- Open Access
- 6 March 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (8)
Tumor cell–derived IFN spatially reprograms osteopontin-enriched macrophage niches to promote PARP inhibitor resistance
Poly (ADP-ribose) polymerase inhibitors (PARPis) benefit homologous recombination-deficient (HRD) malignancies, yet resistance remains a major challenge. Leveraging specimens from a prospective neoadjuvant niraparib monotherapy trial in treatment-naive, high-grade serous ovarian cancer, we integrated PhenoCycler-Fusion spatial profiling, scRNA-Seq, and multiplex immunohistochemistry to identify 2 therapeutic-modulated cellular neighborhoods: an IFN + tumor cell–enriched niche that expands in resistant lesions and a niche enriched in tumor-associated macrophage (TAM) that persists but acquires enhanced immunosuppressive features. Mechanistically, sustained tumor cell–derived IFN induced osteopontin (SPP1) expression in TAMs via STAT signaling, creating immunosuppressive niches enriched in Tregs and myofibroblastic cancer–associated fibroblasts with intensified cell-cell interactions. SPP1 directly suppressed T cell signaling and effector function. High baseline SPP1 + cells predicted lower response rate (30.0% vs. 76.2%; P = 0.021) and shorter progression-free survival (median 13.5 vs. 28.3 months; P = 0.0006). In HRD mouse models, SPP1 blockade restored PARPi sensitivity, reversed acquired resistance, and enhanced T cell cytotoxicity—effects abrogated in immunodeficient mice, confirming immune dependence. These data establish a spatial IFN-SPP1 axis whereby persistent tumor cell IFN reprograms TAMs to promote PARPi resistance, position SPP1 as a key therapeutic target and prognostic biomarker for this therapy, and underscore therapeutic potential of microenvironment-targeted strategies to overcome PARPi resistance.
- 6 March 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (8)
Open AccessTumor cell–derived IFN spatially reprograms osteopontin-enriched macrophage niches to promote PARP inhibitor resistance
Poly (ADP-ribose) polymerase inhibitors (PARPis) benefit homologous recombination-deficient (HRD) malignancies, yet resistance remains a major challenge. Leveraging specimens from a prospective neoadjuvant niraparib monotherapy trial in treatment-naive, high-grade serous ovarian cancer, we integrated PhenoCycler-Fusion spatial profiling, scRNA-Seq, and multiplex immunohistochemistry to identify 2 therapeutic-modulated cellular neighborhoods: an IFN + tumor cell–enriched niche that expands in resistant lesions and a niche enriched in tumor-associated macrophage (TAM) that persists but acquires enhanced immunosuppressive features. Mechanistically, sustained tumor cell–derived IFN induced osteopontin (SPP1) expression in TAMs via STAT signaling, creating immunosuppressive niches enriched in Tregs and myofibroblastic cancer–associated fibroblasts with intensified cell-cell interactions. SPP1 directly suppressed T cell signaling and effector function. High baseline SPP1 + cells predicted lower response rate (30.0% vs. 76.2%; P = 0.021) and shorter progression-free survival (median 13.5 vs. 28.3 months; P = 0.0006). In HRD mouse models, SPP1 blockade restored PARPi sensitivity, reversed acquired resistance, and enhanced T cell cytotoxicity—effects abrogated in immunodeficient mice, confirming immune dependence. These data establish a spatial IFN-SPP1 axis whereby persistent tumor cell IFN reprograms TAMs to promote PARPi resistance, position SPP1 as a key therapeutic target and prognostic biomarker for this therapy, and underscore therapeutic potential of microenvironment-targeted strategies to overcome PARPi resistance.
- Open Access
- 28 February 2026
- Published by Springer Nature in Cancer Imaging
- Vol. 26 (1)
Deep learning prediction model based on multi-modal transvaginal ultrasound scan images for endometrial cancer
Ultrasound-based deep learning (DL) models for the precise diagnosis of endometrial cancer are insufficient. Our aim is to develop and validate an automati
- 28 February 2026
- Published by Springer Nature in Cancer Imaging
- Vol. 26 (1)
Open AccessDeep learning prediction model based on multi-modal transvaginal ultrasound scan images for endometrial cancer
Ultrasound-based deep learning (DL) models for the precise diagnosis of endometrial cancer are insufficient. Our aim is to develop and validate an automati
- Open Access
- 9 February 2026
- Published by Elsevier in SSRN Electronic Journal
Neoadjuvant Niraparib Monotherapy for Newly Diagnosed Unresectable HRD-Positive High-Grade Serous Ovarian Cancer (NANT): A Multicenter, Prospective, Phase 2 Trial
Background Neoadjuvant chemotherapy followed by interval debulking surgery (IDS) is standard for advanced ovarian cancer unlikely to achieve optimal cytoreduction, yet non-cytotoxic neoadjuvant options remain limited. We evaluated whether a chemotherapy-sparing neoadjuvant PARP inhibitor strategy can enable high-quality cytoreduction (R0 resection) while preserving downstream treatment deliverability, including maintenance therapy. Methods In this multicenter, prospective, single-arm, phase 2 trial (NANT), treatment-naïve patients with unresectable FIGO stage III–IV HRD-positive high-grade serous ovarian cancer were selected for a neoadjuvant approach using prespecified resectability criteria and multidisciplinary assessment. They received oral niraparib for two 28-day cycles with an individualized starting dose. Co-primary endpoints were investigator-assessed objective response rate (ORR) and R0 resection rate at IDS. Findings Between Jan 8, 2021, and Jul 18, 2023, 127 widely disseminated, unresectable patients were screened and 67 were enrolled. Among 48 response-evaluable patients, ORR was 62·5%, and the disease control rate was 87·5%. Activity was most pronounced in BRCA1/2-mutated tumors, with an ORR of 77·3% and 100% DCR. Of 40 patients undergoing IDS, 80·0% achieved R0 resection. Complex procedures were common, including bowel resection in 47·5% and upper abdominal procedures in 50·0%, with no perioperative mortality. 81·6% (31/38) achieved CR or PR after postoperative standard chemotherapy and a median maintenance therapy time was 13·6 months. At data cutoff on Dec 29, 2025, with a median 37·7 months follow-up, median progression-free survival was 19·7 months, and median overall survival was 53·2 months. Toxicities were manageable with dose modification and no treatment-related death occurred.Interpretation: Chemotherapy-free neoadjuvant niraparib showed meaningful activity and enabled high rates of complete cytoreduction, while preserving access to postoperative therapies. These findings support this strategy as a potential chemotherapy-sparing alternative for HRD-positive disease, particularly for patients with BRCA1/2 mutations.
- 9 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessNeoadjuvant Niraparib Monotherapy for Newly Diagnosed Unresectable HRD-Positive High-Grade Serous Ovarian Cancer (NANT): A Multicenter, Prospective, Phase 2 Trial
Background Neoadjuvant chemotherapy followed by interval debulking surgery (IDS) is standard for advanced ovarian cancer unlikely to achieve optimal cytoreduction, yet non-cytotoxic neoadjuvant options remain limited. We evaluated whether a chemotherapy-sparing neoadjuvant PARP inhibitor strategy can enable high-quality cytoreduction (R0 resection) while preserving downstream treatment deliverability, including maintenance therapy. Methods In this multicenter, prospective, single-arm, phase 2 trial (NANT), treatment-naïve patients with unresectable FIGO stage III–IV HRD-positive high-grade serous ovarian cancer were selected for a neoadjuvant approach using prespecified resectability criteria and multidisciplinary assessment. They received oral niraparib for two 28-day cycles with an individualized starting dose. Co-primary endpoints were investigator-assessed objective response rate (ORR) and R0 resection rate at IDS. Findings Between Jan 8, 2021, and Jul 18, 2023, 127 widely disseminated, unresectable patients were screened and 67 were enrolled. Among 48 response-evaluable patients, ORR was 62·5%, and the disease control rate was 87·5%. Activity was most pronounced in BRCA1/2-mutated tumors, with an ORR of 77·3% and 100% DCR. Of 40 patients undergoing IDS, 80·0% achieved R0 resection. Complex procedures were common, including bowel resection in 47·5% and upper abdominal procedures in 50·0%, with no perioperative mortality. 81·6% (31/38) achieved CR or PR after postoperative standard chemotherapy and a median maintenance therapy time was 13·6 months. At data cutoff on Dec 29, 2025, with a median 37·7 months follow-up, median progression-free survival was 19·7 months, and median overall survival was 53·2 months. Toxicities were manageable with dose modification and no treatment-related death occurred.Interpretation: Chemotherapy-free neoadjuvant niraparib showed meaningful activity and enabled high rates of complete cytoreduction, while preserving access to postoperative therapies. These findings support this strategy as a potential chemotherapy-sparing alternative for HRD-positive disease, particularly for patients with BRCA1/2 mutations.
- Open Access
- 27 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1)
Aurora kinase B phosphorylates ZBP1 to drive PANoptosis following treatment with PARP and ATR inhibitors combination
The combination of DNA damage response inhibitors (DDR inhibitors) has emerged as a promising strategy for anticancer therapy. Herein, we demonstrate that the combined administration of poly (ADP-ribose) polymerase (PARP) and ataxia telangiectasia and Rad3-related (ATR) inhibitors elicits PANoptosis across diverse cellular lineages, including non-cancerous cell populations. The induction of PANoptosis is dependent on mitotic entry and ZBP1-dependent PANoptosome (ZBP1-RIPK1-Caspase8-Caspase6). We identify the Aurora kinase B (AURKB) as the upstream regulator, essential for phosphorylation of ZBP1 which impacts ZBP1-dependent PANoptosome assembly and activation. The Trp53-/- Brca1-/- model of ID8 and two patient-derived xenograft (PDX) models further confirm the occurrence of PANoptosis following combination administration in vivo. The toxicity is mitigated in ZBP1-knockout mice. This study unveils a mechanism that dictates cell fate during DDR inhibitors-induced aberrant mitosis, emphasizing the critical balance between efficacy and safety in optimizing DDR inhibitors combination therapies.
- 27 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1)
Open AccessAurora kinase B phosphorylates ZBP1 to drive PANoptosis following treatment with PARP and ATR inhibitors combination
The combination of DNA damage response inhibitors (DDR inhibitors) has emerged as a promising strategy for anticancer therapy. Herein, we demonstrate that the combined administration of poly (ADP-ribose) polymerase (PARP) and ataxia telangiectasia and Rad3-related (ATR) inhibitors elicits PANoptosis across diverse cellular lineages, including non-cancerous cell populations. The induction of PANoptosis is dependent on mitotic entry and ZBP1-dependent PANoptosome (ZBP1-RIPK1-Caspase8-Caspase6). We identify the Aurora kinase B (AURKB) as the upstream regulator, essential for phosphorylation of ZBP1 which impacts ZBP1-dependent PANoptosome assembly and activation. The Trp53-/- Brca1-/- model of ID8 and two patient-derived xenograft (PDX) models further confirm the occurrence of PANoptosis following combination administration in vivo. The toxicity is mitigated in ZBP1-knockout mice. This study unveils a mechanism that dictates cell fate during DDR inhibitors-induced aberrant mitosis, emphasizing the critical balance between efficacy and safety in optimizing DDR inhibitors combination therapies.
- 31 May 2025
- Published by Springer Nature in Oncogene
- p. 1-12
LOXL2 reduces susceptibility to PARP inhibitors by promoting super-enhancer-regulated DNA damage repair in high-grade serous ovarian cancer
Poly(ADP-ribose) polymerase inhibitors (PARPi) have revolutionized the treatment of homologous recombination-deficient (HRD) tumors, yet their efficacy in homologous recombination-proficient (HRP) tumors is still limited. Here, we pinpoint lysyl oxidase-like 2 (LOXL2) as a key epigenetic regulator driving PARPi resistance. Our study demonstrate that elevated LOXL2 expression correlates with poor prognosis and disease recurrence in high-grade serous ovarian cancer (HGSOC) patients. Functional studies reveal that LOXL2 depletion or pharmacological inhibition synergizes with PARPi to suppress HRP models of both ovarian and breast cancer. Mechanistically, LOXL2 directly interacts with and transcriptionally activates BRD4, a core component of the super-enhancer complex, thereby amplifying the expression of DNA damage repair (DDR) genes such as MDC1, KAT5, and USP7. Strikingly, LOXL2 inhibition induces a “BRCAness” phenotype in HRP tumors, rendering them more susceptible to PARPi by impairing DDR capacity. Combining BET inhibitors with PARPi abrogates LOXL2-mediated resistance, underscoring BRD4 dependency in this process. Our findings establish LOXL2 as a druggable epigenetic target to overcome PARPi resistance in HRP models of multiple tumor types, presenting a therapeutic strategy independent of HR status and holding significant clinical potential for expanding PARPi benefits to a broader patient population.
- 31 May 2025
- Published by Springer Nature in Oncogene
- p. 1-12
LOXL2 reduces susceptibility to PARP inhibitors by promoting super-enhancer-regulated DNA damage repair in high-grade serous ovarian cancer
Poly(ADP-ribose) polymerase inhibitors (PARPi) have revolutionized the treatment of homologous recombination-deficient (HRD) tumors, yet their efficacy in homologous recombination-proficient (HRP) tumors is still limited. Here, we pinpoint lysyl oxidase-like 2 (LOXL2) as a key epigenetic regulator driving PARPi resistance. Our study demonstrate that elevated LOXL2 expression correlates with poor prognosis and disease recurrence in high-grade serous ovarian cancer (HGSOC) patients. Functional studies reveal that LOXL2 depletion or pharmacological inhibition synergizes with PARPi to suppress HRP models of both ovarian and breast cancer. Mechanistically, LOXL2 directly interacts with and transcriptionally activates BRD4, a core component of the super-enhancer complex, thereby amplifying the expression of DNA damage repair (DDR) genes such as MDC1, KAT5, and USP7. Strikingly, LOXL2 inhibition induces a “BRCAness” phenotype in HRP tumors, rendering them more susceptible to PARPi by impairing DDR capacity. Combining BET inhibitors with PARPi abrogates LOXL2-mediated resistance, underscoring BRD4 dependency in this process. Our findings establish LOXL2 as a druggable epigenetic target to overcome PARPi resistance in HRP models of multiple tumor types, presenting a therapeutic strategy independent of HR status and holding significant clinical potential for expanding PARPi benefits to a broader patient population.
- 19 April 2025
- Published by Elsevier in Drug Resistance Updates
- Vol. 81, 101247
PARP inhibition elicits NK cell-associated immune evasion via potentiating HLA-G expression in tumor
- 19 April 2025
- Published by Elsevier in Drug Resistance Updates
- Vol. 81, 101247
PARP inhibition elicits NK cell-associated immune evasion via potentiating HLA-G expression in tumor
- Open Access
- 3 February 2025
- Published by Elsevier in Redox Biology
- Vol. 80, 103528
Niraparib restricts intraperitoneal metastases of ovarian cancer by eliciting CD36-dependent ferroptosis
- 3 February 2025
- Published by Elsevier in Redox Biology
- Vol. 80, 103528
Open AccessNiraparib restricts intraperitoneal metastases of ovarian cancer by eliciting CD36-dependent ferroptosis